


[Home](#) [Molecular Neurobiology](#) [Article](#)

The Glutathione System: A New Drug Target in Neuroimmune Disorders

Published: 22 April 2014

Volume 50, pages 1059–1084, (2014) [Cite this article](#)

Molecular Neurobiology

[Aims and scope](#)[Submit manuscript](#)

[Gerwyn Morris](#), [George Anderson](#), [Olivia Dean](#), [Michael Berk](#), [Piotr Galecki](#), [Marta Martin-Subero](#) & [Michael Maes](#)

4277 Accesses 148 Citations 22 Altmetric 3 Mentions

[Explore all metrics →](#)

Abstract

Glutathione (GSH) has a crucial role in cellular signaling and antioxidant defenses either by reacting directly with reactive oxygen or nitrogen species or by acting as an essential cofactor for GSH S-transferases and glutathione peroxidases. GSH acting in concert with its dependent enzymes, known as the glutathione system, is responsible for the detoxification of reactive oxygen and nitrogen species (ROS/RNS) and electrophiles produced by xenobiotics. Adequate levels of GSH are essential for the optimal functioning of the immune

system in general and T cell activation and differentiation in particular. GSH is a ubiquitous regulator of the cell cycle per se. GSH also has crucial functions in the brain as an antioxidant, neuromodulator, neurotransmitter, and enabler of neuron survival. Depletion of GSH leads to exacerbation of damage by oxidative and nitrosative stress; hypernitrosylation; increased levels of proinflammatory mediators and inflammatory potential; dysfunctions of intracellular signaling networks, e.g., p53, nuclear factor- κ B, and Janus kinases; decreased cell proliferation and DNA synthesis; inactivation of complex I of the electron transport chain; activation of cytochrome c and the apoptotic machinery; blockade of the methionine cycle; and compromised epigenetic regulation of gene expression. As such, GSH depletion has marked consequences for the homeostatic control of the immune system, oxidative and nitrosative stress (O&NS) pathways, regulation of energy production, and mitochondrial survival as well. GSH depletion and concomitant increase in O&NS and mitochondrial dysfunctions play a role in the pathophysiology of diverse neuroimmune disorders, including depression, myalgic encephalomyelitis/chronic fatigue syndrome and Parkinson's disease, suggesting that depleted GSH is an integral part of these diseases. Therapeutical interventions that aim to increase GSH concentrations *in vivo* include *N*-acetyl cysteine; Nrf-2 activation via hyperbaric oxygen therapy; dimethyl fumarate; phytochemicals, including curcumin, resveratrol, and cinnamon; and folate supplementation.

 This is a preview of subscription content, [log in via an institution](#)  to check access.

Access this article

[Log in via an institution](#)

[Buy article PDF USD 39.95](#)

Price excludes VAT (USA)


Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Rent this article via [DeepDyve](#) ↗


[Institutional subscriptions →](#)

Similar content being viewed by others




[Nitrosative Stress, Hypernitrosylation, and Autoimmune Responses to Nitrosylated Protein...](#)

Article | 23 June 2016



[The interplay between oxidative stress and bioenergetic failure in neuropsychiatric...](#)

Article | 20 June 2020



[Plant-Based Extracts and Antioxidants: Implications on Multiple Sclerosis](#)

Chapter | © 2024

References

1. Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC (2009) Mitochondrial glutathione, a key survival antioxidant. *Antioxid Redox Signal* 11:2685–700, PMID: 19558212
[PubMed Central](#) [PubMed](#) [Google Scholar](#)
2. Lushchak VI (2012) Glutathione homeostasis and functions: potential targets for medical interventions. *J Amino Acids* 2012:736837, PMID: 22500213
[PubMed Central](#) [PubMed](#) [Google Scholar](#)

- 3.** Haddad JJ, Harb HL (2005) L-Gamma-glutamyl-L-cysteinyl-glycine (glutathione; GSH) and GSH-related enzymes in the regulation of pro- and anti-inflammatory cytokines: a signaling transcriptional scenario for redox(y) immunologic sensor(s)? *Mol Immunol* 42:987–1014, PMID: 15829290

[CAS](#) [PubMed](#) [Google Scholar](#)

- 4.** Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. *Int J Biochem Cell Biol* 39:44–84, PMID: 16978905

[CAS](#) [PubMed](#) [Google Scholar](#)

- 5.** Oja SS, Jenei Z, Janáky R, Saransaari P, Varga V (1994) Thiol reagents and brain glutamate receptors. *Proc West Pharmacol Soc* 37:59–62

[CAS](#) [PubMed](#) [Google Scholar](#)

- 6.** Makarov P, Kropf S, Wiswedel I, Augustin W, Schild L (2006) Consumption of redox energy by glutathione metabolism contributes to hypoxia/reoxygenation-induced injury in astrocytes. *Mol Cell Biochem* 286:95–101, PMID: 16583144

[CAS](#) [PubMed](#) [Google Scholar](#)

- 7.** Halliwell B, Gutteridge JMC (1989) Free radicals in biology and medicine. Clarendon Press, Oxford

[Google Scholar](#)

- 8.** Cooper AJ, Pulsinelli WA, Duffy TE (1980) Glutathione and ascorbate during ischemia and postischemic reperfusion in rat brain. *J Neurochem* 35:1242–5, PMID: 7452315

9. Kumar C, Igbaria A, D'Autreaux B, Planson AG, Junot C, Godat E, Bachhawat AK, Delaunay-Moisan A, Toledano MB (2011) Glutathione revisited: a vital function in iron metabolism and ancillary role in thiol-redox control. *EMBO J* 30:2044–56.
doi:[10.1038/emboj.2011.105](https://doi.org/10.1038/emboj.2011.105), PMID: 21478822

10. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. *Antioxid Redox Signal* 10:1343–74. doi:[10.1089/ars.2007.1957](https://doi.org/10.1089/ars.2007.1957), PMID: 18522489

11. Sheehan D, Meade G, Foley VM, Dowd CA (2001) Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. *Biochem J* 360:1–16

12. Zhang H, Forman HJ (2009) Redox regulation of gamma-glutamyl transpeptidase. *Am J Respir Cell Mol Biol* 41:509–15

13. Cooper AJL, Hanigan MH (2010) 4.17—Enzymes involved in processing glutathione conjugates. In: *Comprehensive toxicology* 4:323–66. 2nd edition
14. McIlwain CC, Townsend DM, Tew KD (2006) Glutathione S-transferase polymorphisms: cancer incidence and therapy. *Oncogene* 25:1639–48, PMID: 16550164

15. Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH, Green B, Lang NP, Kadlubar FF (2001) Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. *Pharmacogenetics* 11:663–9, PMID: 11692074

16. Fernandes AP, Holmgren A (2004) Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. *Antioxid Redox Signal* 6:63–74, PMID: 14713336

17. Johnson WM, Wilson-Delfosse AL, Mieyal JJ (2012) Dysregulation of glutathione homeostasis in neurodegenerative diseases. *Nutrients* 4:1399–440.
doi:[10.3390/nu4101399](https://doi.org/10.3390/nu4101399), PMID: 23201762

18. Peltoniemi M, Kaarteenaho-Wiik R, Säily M, Sormunen R, Pääkkö P, Holmgren A, Soini Y, Kinnula VL (2004) Expression of glutaredoxin is highly cell specific in human lung and is decreased by transforming growth factor-beta in vitro and in interstitial lung diseases in vivo. *Hum Pathol* 35:1000–7, PMID: 15297967

19. Pai HV, Starke DW, Lesnefsky EJ, Hoppel CL, Mieyal JJ (2007) What is the functional significance of the unique location of glutaredoxin 1 (GRx1) in the intermembrane space of mitochondria? *Antioxid Redox Signal* 9:2027–33, PMID: 17845131

20. Hinchman CA, Ballatori N (1994) Glutathione conjugation and conversion to mercapturic acids can occur as an intrahepatic process. *J Toxicol Environ Health* 41:387–409

21. Kalyanaraman B, Karoui H, Singh RJ, Felix CC (1996) Detection of thiyl radical adducts formed during hydroxyl radical- and peroxynitrite-mediated oxidation of thiols—a high resolution ESR spin-trapping study at Q-band (35 Ghz). *Anal Biochem* 241:75–81

22. Gardner JM, Aust SD (2009) Quantification of hydroxyl radical produced during phacoemulsification. *J Cataract Refract Surg* 35:2149–53, PMID: 19969222

23. Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, Butterfield DA (2009) Nitric oxide in cell survival: a Janus molecule. *Antioxid Redox Signal* 11:2717–39

24. Siems W, Crifo C, Capuozzo E, Uchida K, Grune T, Salerno C (2010) Metabolism of 4-hydroxy-2-nonenal in human polymorphonuclear leukocytes. *Arch Biochem Biophys* 503:248–52

25. Zhu X, Gallogly MM, Mieyal JJ, Anderson VE, Sayre LM (2009) Covalent cross-linking of glutathione and carnosine to proteins by 4-oxo-2-nonenal. *Chem Res Toxicol*

26. Jones DP, Park Y, Gletsu-Miller N, Liang Y, Yu T, Accardi CJ, Ziegler TR (2011) Dietary sulfur amino acid effects on fasting plasma cysteine/cystine redox potential in humans. *Nutrition* 27:199–205, PMID: 20471805

27. Jones DP (2002) Redox potential of GSH/GSSG couple: assay and biological significance. *Methods Enzymol* 348:93–112

28. Holmgren A, Sengupta R (2010) The use of thiols by ribonucleotide reductase. *Free Radical Biol Med* 49:1617–28

29. Yang Y, Sharma R, Sharma A, Awasthi S, Awasthi YC (2003) Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. *Acta Biochim Pol* 50:319–36

30. Zhang D, Lu H, Li J, Shi X, Huang C (2006) Essential roles of ERKs and p38K in up-regulation of GST A1 expression by Maotai content in human hepatoma cell line Hep3B. *Mol Cell Biochem* 293:161–71, PMID: 16786188

31. Yang Y, Cheng JZ, Singhal SS, Saini M, Pandya U, Awasthi S, Awasthi YC (2001) Role of glutathione S-transferases in protection against lipid peroxidation. Overexpression of hGSTA2-2 in K562 cells protects against hydrogen peroxide-induced apoptosis and inhibits JNK and caspase 3 activation. *J Biol Chem* 276:19220–30, PMID: 11279091

[CAS](#) [PubMed](#) [Google Scholar](#)

32. Sakai M, Muramatsu M (2007) Regulation of glutathione transferase P: a tumor marker of hepatocarcinogenesis. *Biochem Biophys Res Commun* 357:575–8, PMID: 17434454

[CAS](#) [PubMed](#) [Google Scholar](#)

33. Li Y, Cohenford MA, Dutta U, Dain JA (2008) The structural modification of DNA nucleosides by nonenzymatic glycation: an in vitro study based on the reactions of glyoxal and methylglyoxal with 2'-deoxyguanosine. *Anal Bioanal Chem* 390:679–88

[CAS](#) [PubMed](#) [Google Scholar](#)

34. Karlson EW, Watts J, Signorovitch J, Bonetti M, Wright E, Cooper GS, McAlindon TE, Costenbader KH, Massarotti EM, Fitzgerald LM, Jajoo R, Husni ME, Fossel AH, Pankey H, Ding WZ, Knorr R, Condon S, Fraser PA (2007) Effect of glutathione S-transferase polymorphisms and proximity to hazardous waste sites on time to systemic lupus erythematosus diagnosis: results from the Roxbury Lupus Project. *Arthritis Rheum* 56:244–54, PMID: 17195228

[CAS](#) [PubMed](#) [Google Scholar](#)

35. Gravina P, Spoletini I, Masini S, Valentini A, Vanni D, Paladini E, Bossu P, Caltagirone C, Federici G, Spalletta G, Bernardini S (2011) Genetic polymorphisms of glutathione S-transferases GSTM1, GSTT1, GSTP1 and GSTA1 as risk factors for schizophrenia. *Psychiatry Res* 187:454–6

36. Nafissi S, Saadat I, Saadat M (2011) Genetic polymorphisms of glutathione S-transferase Z1 in an Iranian population. *Mol Biol Rep* 38:3391–4. doi:[10.1007/s11033-010-0447-x](https://doi.org/10.1007/s11033-010-0447-x), PMID: 21107728

37. Williams TA, Mars AE, Buyske SG, Stenroos ES, Wang R, Factura-Santiago MF, Lambert GH, Johnson WG (2007) Risk of autistic disorder in affected offspring of mothers with a glutathione S-transferase P1 haplotype. *Arch Pediatr Adolesc Med* 161:356–61, PMID: 17404132

38. Rezaei Z, Saadat I, Saadat M (2012) Association between three genetic polymorphisms of glutathione S-transferase Z1 (GSTZ1) and susceptibility to bipolar disorder. *Psychiatry Res* 30:166–8. doi:[10.1016/j.psychres.2011.09.002](https://doi.org/10.1016/j.psychres.2011.09.002), PMID: 22374552

39. Lynch T, Price A (2007) The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. *Am Fam Physician* 76:391–6

40. Wu Y, Zhang X, Bardag-Gorce F, Robel RC, Aguilo J, Chen L, Zeng Y, Hwang K, French SW, Lu SC, Wan YJ (2004) Retinoid X receptor alpha regulates glutathione homeostasis and xenobiotic detoxification processes in mouse liver. *Mol Pharmacol* 65:550–7, PMID: 14978233

41. Coles BF, Kadlubar FF (2003) Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? *Biofactors* 17:115–30

42. Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. *Annu Rev Pharmacol Toxicol* 45:51–88

43. Huang KP, Huang FL (2002) Glutathionylation of proteins by glutathione disulfide S-oxide. *Biochem Pharmacol* 64:1049–56, PMID: 12213604

44. Poole LB, Karplus PA, Claiborne A (2004) Protein sulfenic acids in redox signaling. *Annu Rev Pharmacol Toxicol* 44:325–47, PMID: 14744249

45. Holmgren A, Lu J (2010) Thioredoxin and thioredoxin reductase: current research with special reference to human disease. *Biochem Biophys Res Commun* 396:120–4

46. Townsend DM (2008) S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response. *Mol Interv* 7:313–24

47. Mieyal JJ, Gallogly MM, Qanungo S, Sabens EA, Shelton MD (2008) Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. *Antioxid Redox Signal* 10:1941–88

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

48. Manevich Y, Feinstein SI, Fisher AB (2004) Activation of the antioxidant enzyme 1-CYS peroxiredoxin requires glutathionylation mediated by heterodimerization with pi GST. *Proc Natl Acad Sci U S A* 101:3780–5, PMID: 15004285

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

49. Townsend DM, Manevich Y, He L, Hutchens S, Pazoles CJ, Tew KD (2009) Novel role for glutathione S-transferase pi Regulator of protein S-glutathionylation following oxidative and nitrosative stress. *J Biol Chem* 284:436–45.
doi:[10.1074/jbc.M805586200](https://doi.org/10.1074/jbc.M805586200), PMID: 18990698

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

50. Mieyal JJ, Starke DW, Gravina SA, Hocevar BA (1991) Thioltransferase in human red blood cells: kinetics and equilibrium. *Biochemistry* 30:8883–91

[CAS](#) [PubMed](#) [Google Scholar](#)

51. Lind C, Gerdes R, Schuppe-Koistinen I, Cotgreave IA (1998) Studies on the mechanism of oxidative modification of human glyceraldehyde-3-phosphate dehydrogenase by glutathione: catalysis by glutaredoxin. *Biochem Biophys Res Commun* 247:481–6, PMID: 9642155

52. Reddy S, Jones AD, Cross CE, Wong PS, Van Der Vliet A (2000) Inactivation of creatine kinase by *S*-glutathionylation of the active-site cysteine residue. *Biochem J* 347:821–7, PMID: 10769188

53. Pineda-Molina E, Klatt P, Vázquez J, Marina A, García de Lacoba M, Pérez-Sala D, Lamas S (2001) Glutathionylation of the p50 subunit of NF- κ B: a mechanism for redox-induced inhibition of DNA binding. *Biochemistry* 40:14134–42, PMID: 11714266

54. Reynaert NL, van der Vliet A, Guala AS, McGovern T, Hristova M, Pantano C, Heintz NH, Heim J, Ho YS, Matthews DE, Wouters EF, Janssen-Heininger YM (2006) Dynamic redox control of NF- κ B through glutaredoxin-regulated *S*-glutathionylation of inhibitory κ B kinase beta. *Proc Natl Acad Sci U S A* 103:13086–91, PMID: 16916935

55. Rao RK, Clayton LW (2002) Regulation of protein phosphatase 2A by hydrogen peroxide and glutathionylation. *Biochem Biophys Res Commun* 293:610–6

56. Taylor ER, Hurrell F, Shannon RJ, Lin TK, Hirst J, Murphy MP (2003) Reversible glutathionylation of complex I increases mitochondrial superoxide formation. *J Biol Chem* 278:19603–10

57. Chen YR, Chen CL, Pfeiffer DR, Zweier JL (2007) Mitochondrial complex II in the post-ischemic heart: oxidative injury and the role of protein S-glutathionylation. *J Biol Chem* 282:32640–54

[CAS](#) [PubMed](#) [Google Scholar](#)

58. Humphries KM, Juliano C, Taylor SS (2002) Regulation of cAMP-dependent protein kinase activity by glutathionylation. *J Biol Chem* 277:43505–11

[CAS](#) [PubMed](#) [Google Scholar](#)

59. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H (2001) Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. *J Biol Chem* 276:29596–602

[CAS](#) [PubMed](#) [Google Scholar](#)

60. Fratelli M, Demol H, Puype M, Casagrande S, Eberini I, Salmona M, Bonetto V, Mengozzi M, Duffieux F, Miclet E, Bachi A, Vanekerckhove J, Gianazza E, Ghezzi P (2002) Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. *Proc Natl Acad Sci U S A* 99:3505–10

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

61. Brown GC, Borutaite V (2004) Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. *Biochim Biophys Acta* 1658:44–49, PMID: 15282173

[CAS](#) [PubMed](#) [Google Scholar](#)

62. Martínez-Ruiz A, Lamas S (2004) S-nitrosylation: a potential new paradigm in signal transduction. *Cardiovasc Res* 62:43–52, PMID: 15023551

63. Jourd'heuil D, Jourd'heuil FL, Feelisch M (2003) Oxidation and nitrosation of thiols at low micromolar exposure to nitric oxide. Evidence for a free radical mechanism. *J Biol Chem* 278:15720–6

64. Mannick JB, Schonhoff CM (2002) Nitrosylation: the next phosphorylation? *Arch Biochem Biophys* 408:1–6, PMID: 12485597

65. Hogg N (2002) The biochemistry and physiology of S-nitrosothiols. *Ann Rev Pharmacol Toxicol* 42:585–600, PMID: 11807184

66. Martínez-Ruiz A, Lamas S (2007) Signalling by NO-induced protein S-nitrosylation and S-glutathionylation: convergences and divergences. *Cardiovasc Res* 75:220–8, PMID: 17451659

67. Giustarini D, Rossi R, Milzani A, Colombo R, Dalle-Donne I (2004) S-glutathionylation: from redox regulation of protein functions to human diseases. *J Cell Mol Med* 8:201–12, PMID: 15256068

68. Aracena-Parks P, Goonasekera SA, Gilman C, Dirksen RT, Hidalgo C, Hamilton SL (2006) Identification of cysteines involved in S-nitrosylation, S-glutathionylation, and

69. Yang Y, Loscalzo J (2005) *S*-nitrosoprotein formation and localization in endothelial cells. Proc Natl Acad Sci U S A 102:117–22, PMID: 15618409

70. Qanungo S, Starke DW, Pai HV, Mieyal JJ, Nieminen AL (2007) Glutathione supplementation potentiates hypoxic apoptosis by *S*-glutathionylation of p65-NFκB. J Biol Chem 282:18427–36

71. Pineda-Molina E, Klatt P, Vazquez J, Marina A, Garcia DL (2001) Glutathionylation of the p50 subunit of NF-κB: a mechanism for redox-induced inhibition of DNA binding. Biochemistry 40:14134–42

72. Morris G, Maes M (2013) A neuro-immune model of myalgic encephalomyelitis/chronic fatigue syndrome. Metab Brain Dis 28:523–40.
doi:[10.1007/s11011-012-9324-8](https://doi.org/10.1007/s11011-012-9324-8), PMID: 22718491

73. Morris G, Maes M (2012) Increased nuclear factor-κB and loss of p53 are key mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Hypotheses 79:607–13. doi:[10.1016/j.mehy.2012.07.034](https://doi.org/10.1016/j.mehy.2012.07.034), PMID: 22951418

- 74.** Marshall HE, Stamler JS (2001) Inhibition of NF-kappa B by S-nitrosylation. Biochemistry 40:1688–93, PMID: 11327828

[CAS](#) [PubMed](#) [Google Scholar](#)

- 75.** Marshall HE, Hess DT, Stamler JS (2004) S-nitrosylation: physiological regulation of NF-kappaB. Proc Natl Acad Sci U S A 101:8841–2, PMID: 15187230

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

- 76.** Into T, Inomata M, Nakashima M, Shibata K, Häcker H, Matsushita K (2008) Regulation of MyD88-dependent signaling events by S nitrosylation retards toll-like receptor signal transduction and initiation of acute-phase immune responses. Mol Cell Biol 28:1338–47, PMID: 18086890

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

- 77.** Haddad JJ (2002) The involvement of L-gamma-glutamyl-L-cysteinyl-glycine (glutathione/GSH) in the mechanism of redox signaling mediating MAPK(p38)-dependent regulation of pro-inflammatory cytokine production. Biochem Pharmacol 63:305–20, PMID: 11841806

[CAS](#) [PubMed](#) [Google Scholar](#)

- 78.** Haddad JJ (2011) A redox microenvironment is essential for MAPK-dependent secretion of pro-inflammatory cytokines: modulation by glutathione (GSH/GSSG) biosynthesis and equilibrium in the alveolar epithelium. Cell Immunol 270:53–61.
doi:[10.1016/j.cellimm.2011.04.001](https://doi.org/10.1016/j.cellimm.2011.04.001), PMID: 21550026

[CAS](#) [PubMed](#) [Google Scholar](#)

- 79.** Gosset P, Wallaert B, Tonnel AB, Fourneau C (1999) Thiol regulation of the production of TNF- α , IL-6 and IL-8 by human alveolar macrophages. *Eur Respir J* 14:98–105

[CAS](#) [PubMed](#) [Google Scholar](#)

- 80.** Jeannin P, Delneste Y, Lecoanet-Henchoz S, Gauchat JF, Life P, Holmes D, Bonnefoy JY (1995) Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis. *J Exp Med* 182:1785–92, PMID: 7500023

[CAS](#) [PubMed](#) [Google Scholar](#)

- 81.** Neuschwander-Tetri BA, Bellezzo JM, Britton RS, Bacon BR, Fox ES (1996) Thiol regulation of endotoxin-induced release of tumor necrosis factor α from isolated rat Kupffer cells. *Biochem J* 320:1005–10

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

- 82.** Chen CY, Huang YL, Lin TH (1998) Association between oxidative stress and cytokine production in nickel-treated rats. *Arch Biochem Biophys* 356:127–32

[CAS](#) [PubMed](#) [Google Scholar](#)

- 83.** Helbling B, von Overbeck J, Lauterburg BH (1996) Decreased release of glutathione into the systemic circulation of patients with HIV infection. *Eur J Clin Invest* 26:38–44, PMID: 8682153

[CAS](#) [PubMed](#) [Google Scholar](#)

- 84.** Brigelius-Flohé R, Banning A, Kny M, Böll G (2004) Redox events in interleukin-1 signaling. *Arch Biochem Biophys* 423:66–73

[PubMed](#) [Google Scholar](#)

85. Palamara AT, Perno CF, Aquaro S, Bue MC, Dini L, Garaci E (1996) Glutathione inhibits HIV replication by acting at late stages of the virus life cycle. *AIDS Res Hum Retroviruses* 12:1537–41

[CAS](#) [PubMed](#) [Google Scholar](#)

86. Novaes R, Freire-de-Lima CG, de Albuquerque RC, Affonso-Mitidieri OR, Espindola O, Lima MA, de Andrade Serpa MJ, Echevarria-Lima J (2013) Modulation of glutathione intracellular levels alters the spontaneous proliferation of lymphocyte from HTLV-1 infected patients. *Immunobiol* 218:1166–74. doi:[10.1016/j.imbio.2013.04.002](https://doi.org/10.1016/j.imbio.2013.04.002), PMID: 23669236

[CAS](#) [Google Scholar](#)

87. Fraternale A, Paoletti MF, Casabianca A, Orlandi C, Schiavano GF, Chiarantini L, Clayette P, Oiry J, Vogel JU, Cinatl J Jr, Magnani M (2008) Inhibition of murine AIDS by pro-glutathione (GSH) molecules. *Antiviral Res* 77:120–7.
doi:[10.1016/j.antiviral.2007.11.004](https://doi.org/10.1016/j.antiviral.2007.11.004)

[CAS](#) [PubMed](#) [Google Scholar](#)

88. Cai J, Chen Y, Seth S, Furukawa S, Compans RW, Jones DP (2003) Inhibition of influenza infection by glutathione. *Free Radic Biol Med* 34:928–36, PMID: 12654482

[CAS](#) [PubMed](#) [Google Scholar](#)

89. Palamara AT, Perno CF, Ciriolo MR, Dini L, Balestra E, D'Agostini C, Di Francesco P, Favalli C, Rotilio G, Garaci E (1995) Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication. *Antiviral Res* 27:237–53

[CAS](#) [PubMed](#) [Google Scholar](#)

90. Garaci E, Palamara AT, Ciriolo MR, D'Agostini C, Abdel-Latif MS, Aquaro S, Lafavia E, Rotilio G (1997) Intracellular GSH content and HIV replication in human macrophages. *J Leukoc Biol* 62:54–59

[CAS](#) [PubMed](#) [Google Scholar](#)

91. Wang J, Chen Y, Gao N, Wang Y, Tian Y, Wu J, Zhang J, Zhu J, Fan D, An J (2013) Inhibitory effect of glutathione on oxidative liver injury induced by dengue virus serotype 2 infections in mice. *PLoS One* 8:e55407. doi:[10.1371/journal.pone.0055407](https://doi.org/10.1371/journal.pone.0055407)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

92. Tian Y, Jiang W, Gao N, Zhang J, Chen W, Fan D, Zhou D, An J (2010) Inhibitory effects of glutathione on dengue virus production. *Biochem Biophys Res Commun* 397:420–4. doi:[10.1016/j.bbrc.2010.05.108](https://doi.org/10.1016/j.bbrc.2010.05.108)

[CAS](#) [PubMed](#) [Google Scholar](#)

93. Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, Clarke F, Sitia R, Rubartelli A (2002) Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. *Proc Natl Acad Sci U S A* 99:1491–6, PMID: 11792859

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

94. Ishii T, Hishinuma I, Bannai S, Sugita Y (1981) Mechanism of growth promotion of mouse lymphoma L1210 cells in vitro by feeder layer or 2-mercaptoethanol. *J Cell Physiol* 107:283–93, PMID: 7251686

[CAS](#) [PubMed](#) [Google Scholar](#)

95. Yan Z, Garg SK, Kipnis J, Banerjee R (2009) Extracellular redox modulation by regulatory T cells. *Nat Chem Biol* 5:721–3. doi:[10.1038/nchembio.212](https://doi.org/10.1038/nchembio.212), PMID: 19718041

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

96. Sido B, Braunstein J, Breitkreutz R, Herfarth C, Meuer SC (2000) Thiol-mediated redox regulation of intestinal lamina propria T lymphocytes. *J Exp Med* 192:907–12, PMID: 10993921

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

97. Garg SK, Yan Z, Vitvitsky V, Banerjee R (2011) Differential dependence on cysteine from transsulfuration versus transport during T cell activation. *Antioxid Redox Signal* 15:39–47. doi:[10.1089/ars.2010.3496](https://doi.org/10.1089/ars.2010.3496), PMID: 20673163

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

98. Yan Z, Banerjee R (2010) Redox remodeling as an immunoregulatory strategy. *Biochem* 49:1059–66. doi:[10.1021/bi902022n](https://doi.org/10.1021/bi902022n), PMID: 20070126

[CAS](#) [Google Scholar](#)

99. Yan Z, Garg SK, Kipnis J, Banerjee R (2009) Extracellular redox modulation by regulatory T cells. *Nat Chem Biol* 5:721–3. doi:[10.1038/nchembio.212](https://doi.org/10.1038/nchembio.212), PMID: 19718041

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

100. Zahedi Avval F, Holmgren A (2009) Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for mammalian S phase ribonucleotide reductase. *J Biol Chem* 284:8233–40. doi:[10.1074/jbc.M809338200](https://doi.org/10.1074/jbc.M809338200), PMID: 19176520

[PubMed](#) [Google Scholar](#)

101. Suthanthiran M, Anderson ME, Sharma VK, Meister A (1990) Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. *Proc Natl Acad Sci U S A* 87:3343–47, PMID: 1970635

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

102. Messina JP, Lawrence DA (1989) Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. *J Immunol* 143:1974–81

[CAS](#) [PubMed](#) [Google Scholar](#)

103. Yan Z, Garg SK, Banerjee R (2010) Regulatory T cells interfere with glutathione metabolism in dendritic cells and T cells. *J Biol Chem* 285:41525–32.
doi:[10.1074/jbc.M110.189944](https://doi.org/10.1074/jbc.M110.189944), PMID: 21037289

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

104. Kamide Y, Utsugi M, Dobashi K, Ono A, Ishizuka T, Hisada T, Koga Y, Uno K, Hamuro J, Mori M (2011) Intracellular glutathione redox status in human dendritic cells regulates IL-27 production and T-cell polarization. *Allergy* 66:1183–92.
doi:[10.1111/j.1398-9995.2011.02611.x](https://doi.org/10.1111/j.1398-9995.2011.02611.x), PMID: 21545428

[CAS](#) [PubMed](#) [Google Scholar](#)

105. Murata Y, Ohteki T, Koyasu S, Hamuro J (2002) IFN-gamma and pro-inflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension. *Eur J Immunol* 32:2866–73, PMID: 12355439

[CAS](#) [PubMed](#) [Google Scholar](#)

- 106.** Palomares T, Alonso-Varona A, Alvarez A, Castro B, Calle Y, Bilbao P (1997) Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells. *Clin Exp Metastasis* 15:329–37, PMID: 9174132
- [CAS](#) [PubMed](#) [Google Scholar](#)
- 107.** Gmünder H, Roth S, Eck HP, Gallas H, Mihm S, Dröge W (1990) Interleukin-2 mRNA expression, lymphokine production and DNA synthesis in glutathione-depleted T cells. *Cell Immunol* 130:520–8, PMID: 2208308
- [PubMed](#) [Google Scholar](#)
- 108.** Yamauchi A, Bloom ET (1997) Control of cell cycle progression in human natural killer cells through redox regulation of expression and phosphorylation of retinoblastoma gene product protein. *Blood* 89:4092–9, PMID: 9166850
- [CAS](#) [PubMed](#) [Google Scholar](#)
- 109.** Liang CM, Lee N, Cattell D, Liang SM (1989) Glutathione regulates interleukin-2 activity on cytotoxic T-cells. *J Biol Chem* 264:13519–23
- [CAS](#) [PubMed](#) [Google Scholar](#)
- 110.** Chen J, Stewart V, Spyrou G, Hilberg F, Wagner EF, Alt FW (1994) Generation of normal T and B lymphocytes by c-jun deficient embryonic stem cells. *Immunity* 1:65–72
- [CAS](#) [PubMed](#) [Google Scholar](#)
- 111.** Pallardó FV, Markovic J, García JL, Viña J (2009) Role of nuclear glutathione as a key regulator of cell proliferation. *Mol Aspects Med* 30:77–85.

112. Markovic J, García-Gimenez JL, Gimeno A, Viña J, Pallardó FV (2010) Role of glutathione in cell nucleus. *Free Radic Res* 44(7):721–33.
doi:[10.3109/10715762.2010.485989](https://doi.org/10.3109/10715762.2010.485989)

113. Diaz Vivancos P, Wolff T, Markovic J, Pallardó FV, Foyer CH (2010) A nuclear glutathione cycle within the cell cycle. *Biochem J* 431:169–78

114. García-Giménez JL, Markovic J, Dasí F, Queval G, Schnaubelt D, Foyer CH, Pallardó FV (2013) Nuclear glutathione. *Biochim Biophys Acta* 1830:3304–16.
doi:[10.1016/j.bbagen.2012.10.005](https://doi.org/10.1016/j.bbagen.2012.10.005), PMID: 23069719

115. Ashtiani HRA, Bakhshandi AK, Rahbar M, Mirzaei A, Malekpour A, Rastegar H (2011) Glutathione, cell proliferation and differentiation. *Afr J Biotechnol* 10:6348–63

116. Cuadrado A, Garcia-Fernandez LF, Gonzalez L, Suarez Y, Losada A, Alcaide V, Martinez T, Fernandez-Sousa JM, Sanchez-Puelles JM, Munoz A (2003) Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. *J Biol Chem* 278:241–50, PMID: 12414812

117. Day RM, Suzuki YJ (2006) Cell proliferation, reactive oxygen and cellular glutathione. *Dose Response* 3:425–42. doi:[10.2203/dose-response.003.03.010](https://doi.org/10.2203/dose-response.003.03.010), PMID: 18648617

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

118. Circu ML, Aw TY (2008) Glutathione and apoptosis. *Free Radic Res* 42:689–706. doi:[10.1080/10715760802317663](https://doi.org/10.1080/10715760802317663), PMID: 18671159

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

119. Franco R, Cidlowski JA (2009) Apoptosis and glutathione: beyond an antioxidant. *Cell Death Differ* 16:1303–14. doi:[10.1038/cdd.2009.107](https://doi.org/10.1038/cdd.2009.107), PMID: 19662025

[CAS](#) [PubMed](#) [Google Scholar](#)

120. Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. *Cell* 120:483–95, PMID: 15734681

[CAS](#) [PubMed](#) [Google Scholar](#)

121. Bertout JA, Patel SA, Simon MC (2008) The impact of O₂ availability on human cancer. *Nat Rev Cancer* 8:967–75

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

122. Orrenius S, Gogvadze V, Zhivotovsky B (2007) Mitochondrial oxidative stress: implications for cell death. *Annu Rev Pharmacol Toxicol* 47:143–83, PMID: 17029566

[CAS](#) [PubMed](#) [Google Scholar](#)

123. Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, Pacak K, Kass DA, Di Lisa F, Paolocci N (2010) Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. *Circ Res* 106:193–202. doi:[10.1161/CIRCRESAHA.109.198366](https://doi.org/10.1161/CIRCRESAHA.109.198366), PMID: 19910579

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

124. Starkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, Beal MF (2004) Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. *J Neurosci* 24(36):7779–88, PubMed PMID: 15356189

[CAS](#) [PubMed](#) [Google Scholar](#)

125. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J (2010) NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. *Proc Natl Acad Sci U S A* 107:15565–70. doi:[10.1073/pnas.1002178107](https://doi.org/10.1073/pnas.1002178107), PMID: 20713697

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

126. Adam-Vizi V, Chinopoulos C (2006) Bioenergetics and the formation of mitochondrial reactive oxygen species. *Trends Pharmacol Sci* 27:639–45, PMID: 17056127

[CAS](#) [PubMed](#) [Google Scholar](#)

127. Andreyev AY, Kushnareva YE, Starkov AA (2005) Mitochondrial metabolism of reactive oxygen species. *Biochemistry (Mosc)* 70:200–14, PMID: 15807660

[CAS](#) [Google Scholar](#)

128. Murphy MP (2009) How mitochondria produce reactive oxygen species. *Biochem J* 417:1–13. doi:[10.1042/BJ20081386](https://doi.org/10.1042/BJ20081386), PMID: 19061483

129. Cox AG, Winterbourn CC, Hampton MB (2009) Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. *Biochem J* 425:313–25.
doi:[10.1042/BJ20091541](https://doi.org/10.1042/BJ20091541), PMID: 20025614

[PubMed](#) [Google Scholar](#)

130. Aon MA, Cortassa S, O'Rourke B (2010) Redox-optimized ROS balance: a unifying hypothesis. *Biochim Biophys Acta* 1797:865–77. doi:[10.1016/j.bbabi.2010.02.016](https://doi.org/10.1016/j.bbabi.2010.02.016), PMID: 20175987

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

131. Aon MA, Stanley BA, Sivakumaran V, Kembro JM, O'Rourke B, Paolocci N, Cortassa S (2012) Glutathione/thioredoxin systems modulate mitochondrial H₂O₂ emission: an experimental-computational study. *J Gen Physiol* 139:479–91.
doi:[10.1085/jgp.201210772](https://doi.org/10.1085/jgp.201210772), PMID: 22585969

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

132. Sheeran FL, Rydström J, Shakhpargonov MI, Pestov NB, Pepe S (2010) Diminished NADPH transhydrogenase activity and mitochondrial redox regulation in human failing myocardium. *Biochim Biophys Acta* 1797:1138–48.
doi:[10.1016/j.bbabi.2010.04.002](https://doi.org/10.1016/j.bbabi.2010.04.002), PMID: 20388492

[CAS](#) [PubMed](#) [Google Scholar](#)

133. Drechsel DA, Patel M (2010) Respiration-dependent H₂O₂ removal in brain mitochondria via the thioredoxin/peroxiredoxin system. *J Biol Chem* 285:27850–58.
doi:[10.1074/jbc.M110.101196](https://doi.org/10.1074/jbc.M110.101196), PMID: 20558743

134. Go YM, Jones DP (2008) Redox compartmentalization in eukaryotic cells. *Biochim Biophys Acta* 1780:1273–90. doi:[10.1016/j.bbagen.2008.01.011](https://doi.org/10.1016/j.bbagen.2008.01.011), PMID: 18267127

135. Hu J, Dong L, Outten CE (2008) The redox environment in the mitochondrial intermembrane space is maintained separately from the cytosol and matrix. *J Biol Chem* 283:29126–34. doi:[10.1074/jbc.M803028200](https://doi.org/10.1074/jbc.M803028200), PMID: 18708636

136. Kakkar P, Singh BK (2007) Mitochondria: a hub of redox activities and cellular distress control. *Mol Cell Biochem* 305:235–53

137. Koehler CM, Beverly K, Leverich EP (2006) Redox pathways in the mitochondrion. *Antioxid Redox Signal* 8:813–22

138. Pedrajas JR, Kosmidou E, Miranda-Vizuete A, Gustafsson JA, Wright AP, Spyrou G (1999) Identification and functional characterization of a novel mitochondrial thioredoxin system in *Saccharomyces cerevisiae*. *J Biol Chem* 274:6366–73

139. Chae HZ, Kang SW, Rhee SG (1999) Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin. *Methods Enzymol* 300:219–26

140. Orlowski M, Karkowsky A (1976) Glutathione metabolism and some possible functions of glutathione in the nervous system. *Int Rev Neurobiol* 19:75–121, PMID: 13046

141. Hjelle OP, Rinvik E, Huster D, Reichelt W, Ottersen OP (1998) In: Shaw CA (ed) Glutathione in the nervous system. Taylor & Francis, Washington, pp pp. 63–88

142. Nakanishi S (1992) Molecular diversity of glutamate receptors and implications for brain function. *Science* 258:597–603, PMID: 1329206

143. Récasens M, Mayat E, Vignes M (1992) The multiple excitatory amino acid receptor subtypes and their putative interactions. *Mol Neuropharmacol* 2:15–31

144. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. *Science* 262:689–95, PMID: 7901908

145. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. *Ann Neurol* 38:357–66, PMID: 7668820

146. Ogita K, Shuto M, Maeda H, Minami T, Yoneda Y (1998) Possible modulation by glutathione of glutamatergic neurotransmission. In: Shaw CA (ed) Glutathione in the nervous system. Taylor & Francis, Washington, pp pp. 137–161

[Google Scholar](#)

147. Varga V, Janáky R, Saransaari P, Oja SS (1994) Endogenous gamma-L-glutamyl and beta-L-aspartyl peptides and excitatory aminoacidergic neurotransmission in the brain. *Neuropeptides* 27:19–26, PMID: 7969817

148. Oja SS, Janáky R, Varga V, Saransaari P (2000) Modulation of glutamate receptor functions by glutathione. *Neurochem Int* 37:299–306, PMID: 10812215

149. Varga V, Jenei Z, Janáky R, Saransaari P, Oja SS (1997) Glutathione is an endogenous ligand of rat brain N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors. *Neurochem Res* 22:1165–71, PMID: 9251108

150. Matsuda T, Shimizu E, Ikehira H, Iyo M, Hashimoto K (2008) Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3 T 1H-MRS study. *PLoS One* 3:e1944, PMID: 18398470

- 151.** Janáky R, Ogita K, Pasqualotto BA, Bains JS, Oja SS, Yoneda Y, Shaw CA (1999) Glutathione and signal transduction in the mammalian CNS. *J Neurochem* 73:889–902, PMID: 10461878

[PubMed](#) [Google Scholar](#)

- 152.** Varga V, Janáky R, Marnela KM, Gulyás J, Kontro P, Oja SS (1989) Displacement of excitatory amino acid receptor ligands by acidic oligopeptides. *Neurochem Res* 14:1223–7, PMID: 2576463

[CAS](#) [PubMed](#) [Google Scholar](#)

- 153.** Jenei Z, Janáky R, Varga V, Saransaari P, Oja SS (1998) Interference of S-alkyl derivatives of glutathione with brain ionotropic glutamate receptors. *Neurochem Res* 23:1085–91, PMID: 9704598

[CAS](#) [PubMed](#) [Google Scholar](#)

- 154.** Gilbert KR, Aizenman E, Reynolds IJ (1991) Oxidized glutathione modulates N-methyl-D-aspartate- and depolarization-induced increases in intracellular Ca²⁺ in cultured rat forebrain neurons. *Neurosci Lett* 133:11–4, PMID: 1838798

[CAS](#) [PubMed](#) [Google Scholar](#)

- 155.** Cooper AJL (1997) Role of astrocytes in maintaining cerebral glutathione homeostasis and in protecting the brain against xenobiotics and oxidative stress. In: Shaw CA (ed) Glutathione in the nervous system. Taylor and Francis, Washington, pp 91–1–115

[Google Scholar](#)

- 156.** Levy DI, Sucher NJ, Lipton SA (1991) Glutathione prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. *Neuroreport* 2:345–47, PMID: 1832987

157. Owe SG, Marcaggi P, Attwell D (2006) The ionic stoichiometry of the GLAST glutamate transporter in salamander retinal glia. *J Physiol* 577:591–9, PMID: 17008380

158. Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J, Danbolt NC (1995) Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. *J Neurosci* 15:1835–53, PMID: 7891138

159. Tanaka K (2000) Functions of glutamate transporters in the brain. *Neurosci Res* 37:15–9, PMID: 10802340

160. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M, Wada K (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. *Science* 276:1699–1702, PMID: 9180080

161. Takaki J, Fujimori K, Miura M, Suzuki T, Sekino Y, Sato K (2012) L-glutamate released from activated microglia downregulates astrocytic L-glutamate transporter expression in neuroinflammation: the ‘collusion’ hypothesis for increased extracellular L-glutamate concentration in neuroinflammation. *J Neuroinflammation* 9:275. doi:[10.1186/1742-2094-9-275](https://doi.org/10.1186/1742-2094-9-275). PMID: 23259598

162. Bassi MT, Gasol E, Manzoni M, Pineda M, Riboni M, Martin R, Zorzano A, Borsani G, Palacin M (2001) Identification and characterisation of human xCT that co-expresses, with 4 F2 heavy chain, the amino acid transport activity system x_c . *Pflugers Arch* 442:286–96

163. Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K, Moriguchi T, Takahashi S, Bannai S (2005) Redox imbalance in cystine/glutamate transporter-deficient mice. *J Biol Chem* 280:37423–9, PMID: 16144837

164. Allen JW, Shanker G, Aschner M (2001) Methylmercury inhibits the in vitro uptake of the glutathione precursor, cystine, in astrocytes, but not in neurons. *Brain Res* 894:131–40

165. Qin S, Colin C, Hinnens I, Gervais A, Cheret C, Mallat M (2006) System Xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1–40. *J Neurosci* 26:3345–56, PMID: 16554485

166. Barger SW, Goodwin ME, Porter MM, Beggs ML (2007) Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. *J Neurochem* 101:1205–13

167. Kidd PM (2003) Glutathione: Systemic protectant against oxidative and free radical damage. *Alt Med Rev* 2:155–76

[Google Scholar](#)

168. Gardner JM, Aust SD (2009) Quantification of hydroxyl radical produced during phacoemulsification. *J Cataract Refract Surg* 35:2149–53

[PubMed](#) [Google Scholar](#)

169. Sagone AL Jr, Husney RM, O'Dorisio MS, Metz EN (1984) Mechanisms for the oxidation of reduced glutathione by stimulated granulocytes. *Blood* 63:96–104

[CAS](#) [PubMed](#) [Google Scholar](#)

170. Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, Butterfield DA (2009) Nitric oxide in cell survival: a Janus molecule. *Antioxid Redox Signal* 11:2717–39

[CAS](#) [PubMed](#) [Google Scholar](#)

171. Chang HL, Dedon PC, Deen WM (2008) Kinetic analysis of intracellular concentrations of reactive nitrogen species. *Chem Res Toxicol* 21:2134–47

[Google Scholar](#)

172. Siems W, Crifo C, Capuozzo E, Uchida K, Grune T, Salerno C (2010) Metabolism of 4-hydroxy-2-nonenal in human polymorphonuclear leukocytes. *Arch Biochem Biophys* 503:248–52

173. Zhu X, Gallogly MM, Mieyal JJ, Anderson VE, Sayre LM (2009) Covalent cross-linking of glutathione and carnosine to proteins by 4-oxo-2-nonenal. *Chem Res Toxicol* 22:1050–9

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

174. Lushchak VI (2011) Adaptive response to oxidative stress: bacteria, fungi, plants and animals. *Comp Biochem Physiol C Toxicol Pharmacol* 153:175–190

[PubMed](#) [Google Scholar](#)

175. Lushchak VI (2011) Environmentally induced oxidative stress in aquatic animals. *Aquatic Toxicol* 101:13–30

[CAS](#) [Google Scholar](#)

176. Belrose JC, Xie YF, Gierszewski LJ, MacDonald JF, Jackson MF (2012) Loss of glutathione homeostasis associated with neuronal senescence facilitates TRPM2 channel activation in cultured hippocampal pyramidal neurons. *Mol Brain* 5:11. doi:[10.1186/1756-6606-5-11](https://doi.org/10.1186/1756-6606-5-11), PMID: 22487454

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

177. Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. *Biol Chem* 384:505–16

[CAS](#) [PubMed](#) [Google Scholar](#)

178. Lu GD, Shen HM, Chung MC, Ong CN (2007) Critical role of oxidative stress and sustained JNK activation in aloe-emodin-mediated apoptotic cell death in human

hepatoma cells. *Carcinogenesis* 28:1937–45, PMID: 17698970

[CAS](#) [PubMed](#) [Google Scholar](#)

179. Neuschwander-Tetri BA, Bellezzi JM, Britton RS, Bacon BR, Fox ES (1996) Thiol regulation of endotoxin-induced release of tumour necrosis factor alpha from isolated rat Kupffer cells. *Biochem J* 320:1005–10, PMID: 9003392

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

180. Nikulina MA, Andersen HU, Karlsen AE, Darville MI, Eizirik DL, Mandrup-Poulsen T (2000) Glutathione depletion inhibits interleukin 1 beta-stimulated nitric oxide production by reducing inducible nitric oxide synthase gene expression. *Cytokine+* 12:1391–4

[CAS](#) [PubMed](#) [Google Scholar](#)

181. Peristeris P, Clark BD, Gatti S, Faggini R, Mantovani A, Mengozzi M, Orencole SF, Sironi M, Ghezzi P (1992) N-acetylcysteine and glutathione as inhibitors of tumour necrosis factor production. *Cell Immunol* 140:390–9

[CAS](#) [PubMed](#) [Google Scholar](#)

182. Robinson MK, Roderick ML, Jacobs DO, Rounds JD, Collins KH, Saporoschek IB, Mannick JA, Wilmore DW (1993) Glutathione depletion in rats impairs T-cell and macrophage immune function. *Arch Surg* 128:29–35

[CAS](#) [PubMed](#) [Google Scholar](#)

183. Komatsu H, Hoshino A, Funayama M, Kawahara K, Obala F (2003) Oxidative modulation of the glutathione-redox couple enhances lipopolysaccharide-induced

interleukin 12 P40 production by a mouse macrophage cell line, J774A.1. Free Radic Res 37:293–9

[CAS](#) [PubMed](#) [Google Scholar](#)

184. Grimble RF (2006) The effects of sulfur amino acid intake on immune function in humans. *J Nutr* 136:1660S–5S, PMID: 16702336

[CAS](#) [PubMed](#) [Google Scholar](#)

185. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C (1998) Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. *Proc Natl Acad Sci U S A* 95:3071–6, PMID: 9501217

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

186. Won HY, Sohn JH, Min HJ, Lee K, Woo HA, Ho YS, Park JW, Rhee SG, Hwang ES (2010) Glutathione peroxidase 1 deficiency attenuates allergen-induced airway inflammation by suppressing Th2 and Th17 cell development. *Antioxid Redox Signal* 13:575–87. doi:[10.1089/ars.2009.2989](https://doi.org/10.1089/ars.2009.2989), PMID: 20367278

[CAS](#) [PubMed](#) [Google Scholar](#)

187. Li W, Busu C, Circu ML, Aw TY (2012) Glutathione in cerebral microvascular endothelial biology and pathobiology: implications for brain homeostasis. *Int J Cell Biol* 2012:434971. doi:[10.1155/2012/434971](https://doi.org/10.1155/2012/434971), PMID: 22745639

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

188. Velu CS, Niture SK, Doneanu CE, Pattabiraman N, Srivenugopal KS (2007) Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. *Biochem* 46:7765–80, PMID: 17555331

189. Qanungo S, Starke DW, Pai HV, Mieyal JJ, Nieminen AL (2007) Glutathione supplementation potentiates hypoxic apoptosis by S-glutathionylation of p65-NFκB. *J Biol Chem* 282:18427–36, PMID: 17468103

[CAS](#) [PubMed](#) [Google Scholar](#)

190. Staal FJ (1998) Glutathione and HIV infection: reduced reduced, or increased oxidized? *Eur J Clin Invest* 28:194–6, PMID: 9568464

[CAS](#) [PubMed](#) [Google Scholar](#)

191. Kurdi M, Sivakumaran V, Duhé RJ, Aon MA, Paolocci N, Booz GW (2012) Depletion of cellular glutathione modulates LIF-induced JAK1-STAT3 signaling in cardiac myocytes. *Int J Biochem Cell Biol* 44:2106–15. doi:[10.1016/j.biocel.2012.08.016](https://doi.org/10.1016/j.biocel.2012.08.016), PMID: 22939972

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

192. Zeevalk GD, Manzino L, Sonsalla PK, Bernard LP (2007) Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. *Exp Neurol* 203(2):512–20, PMID: 17049515

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

193. Shen H, Liu Z (2006) JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. *Free Rad Biol Med* 40:928–39

[CAS](#) [PubMed](#) [Google Scholar](#)

194. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, Rakic P, Flavell RA (2004) JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. *Proc Natl Acad Sci U S A* 101:665–70

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

195. Garcia-Gimenez JL, Markovic J, Dasi F, Queval G, Schnaubelt D, Foyer CH, Pallardo FV (2013) Nuclear glutathione. *Biochim Biophys Acta* 1830:3304–16

[CAS](#) [PubMed](#) [Google Scholar](#)

196. Markovic J, Mora NJ, Broseta AM, Gimeno A, de-la Concepción N, Vina J, Pallardo FV (2009) The depletion of nuclear glutathione impairs cell proliferation in 3 t3 fibroblasts. *PLoS One* 4:e6413. doi:[10.1371/journal.pone.0006413](https://doi.org/10.1371/journal.pone.0006413)

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

197. Takahashi T, Tabuchi T, Tamaki Y, Kosaka K, Takikawa Y, Satoh T (2009) Carnosic acid and carnosol inhibit adipocyte differentiation in mouse 3 T3-L1 cells through induction of phase2 enzymes and activation of glutathione metabolism. *Biochem Biophys Res Commun* 382:549–54. doi:[10.1016/j.bbrc.2009.03.059](https://doi.org/10.1016/j.bbrc.2009.03.059), PMID: 19289108

[CAS](#) [PubMed](#) [Google Scholar](#)

198. Messina JP, Lawrence DA (1989) Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. *J Immunol* 143:1974–81, PMID: 2789253

[CAS](#) [PubMed](#) [Google Scholar](#)

199. Markovic J, Borrás C, Ortega A, Sastre J, Viña J, Pallardó FV (2007) Glutathione is recruited into the nucleus in early phases of cell proliferation. *J Biol Chem* 282:20416–24, PMID: 17452333

[CAS](#) [PubMed](#) [Google Scholar](#)

200. Atkuri KR, Cowan TM, Kwan T, Ng A, Herzenberg LA, Herzenberg LA, Enns GM (2009) Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia. *Proc Natl Acad Sci U S A* 106:3941–5. doi:[10.1073/pnas.0813409106](https://doi.org/10.1073/pnas.0813409106), PMID: 19223582

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

201. Vali S, Mythri RB, Jagatha B, Padiadpu J, Ramanujan KS, Andersen JK, Gorin F, Bharath MM (2007) Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson’s disease: a dynamic model. *Neuroscience* 149:917–30, PMID: 17936517

[CAS](#) [PubMed](#) [Google Scholar](#)

202. Hargreaves IP, Sheena Y, Land JM, Heales SJ (2005) Glutathione deficiency in patients with mitochondrial disease: implications for pathogenesis and treatment. *J Inherit Metab Dis* 28:81–8, PMID: 15702408

[CAS](#) [PubMed](#) [Google Scholar](#)

203. Pastore A, Petrillo S, Tozzi G, Carrozzo R, Martinelli D, Dionisi-Vici C, Di Giovamberardino G, Ceravolo F, Klein MB, Miller G, Enns GM, Bertini E, Piemonte F (2013) Glutathione: a redox signature in monitoring EPI-743 therapy in children with mitochondrial encephalomyopathies. *Mol Genet Metab* 109:208–14. doi:[10.1016/j.ymgme.2013.03.011](https://doi.org/10.1016/j.ymgme.2013.03.011), PMID: 23583222

204. Salmi H, Leonard JV, Rahman S, Lapatto R (2012) Plasma thiol status is altered in children with mitochondrial diseases. *Scand J Clin Lab Invest* 72:152–7.
doi:[10.3109/00365513.2011.646299](https://doi.org/10.3109/00365513.2011.646299), PMID: 22208644

205. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA (2007) N-acetylcysteine—a safe antidote for cysteine/glutathione deficiency. *Curr Opin Pharmacol* 7:355–9, PMID: 17602868

206. Waly MI, Hornig M, Trivedi M, Hodgson N, Kini R, Ohta A, Deth R (2012) Prenatal and postnatal epigenetic programming: implications for GI, immune, and neuronal function in autism. *Autism Res Treat* 2012:190930. doi:[10.1155/2012/190930](https://doi.org/10.1155/2012/190930), PMID: 22934169

207. Kang PT, Zhang L, Chen CL, Chen J, Green KB, Chen YR (2012) Protein thiyl radical mediates S-glutathionylation of complex I. *Free Radic Biol Med* 53:962–73.
doi:[10.1016/j.freeradbiomed.2012.05.025](https://doi.org/10.1016/j.freeradbiomed.2012.05.025), PMID: 22634394

208. Townsend DM, Manevich Y, He L, Hutchens S, Pazoles CJ, Tew KD (2009) Novel role for glutathione S-transferase piRegulator of protein S-glutathionylation following oxidative and nitrosative stress. *J Biol Chem* 284:436–45.
doi:[10.1074/jbc.M805586200](https://doi.org/10.1074/jbc.M805586200), PMID: 18990698

209. Borutaite V, Brown GC (2007) Mitochondrial regulation of caspase activation by cytochrome oxidase and tetramethylphenylenediamine via cytosolic cytochrome c redox state. *J Biol Chem* 282:31124–30, PMID: 17690099

210. Vaughn AE, Deshmukh M (2008) Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. *Nat Cell Biol* 10:1477–83.
doi:[10.1038/ncb1807](https://doi.org/10.1038/ncb1807), PMID: 19029908

211. Kizhakkayil J, Thayyullathil F, Chathoth S, Hago A, Patel M, Galadari S (2012) Glutathione regulates caspase-dependent ceramide production and curcumin-induced apoptosis in human leukemic cells. *Free Radic Biol Med* 52:1854–64.
doi:[10.1016/j.freeradbiomed.2012.02.026](https://doi.org/10.1016/j.freeradbiomed.2012.02.026), PMID: 22387197

212. Martín SF, Sawai H, Villalba JM, Hannun YA (2007) Redox regulation of neutral sphingomyelinase-1 activity in HEK293 cells through a GSH-dependent mechanism. *Arch Biochem Biophys* 459:295–300, PMID: 17169322

213. Lou H, Kaplowitz N (2007) Glutathione depletion down-regulates tumor necrosis factor alpha-induced NF-κappaB activity via IkappaB kinase-dependent and -independent mechanisms. *J Biol Chem* 282:29470–81, PMID: 17690092

214. Franco R, Cidlowski JA (2009) Apoptosis and glutathione: beyond an antioxidant. *Cell Death Differ* 16:1303–14. doi:[10.1038/cdd.2009.107](https://doi.org/10.1038/cdd.2009.107), PMID: 19662025

215. Allen EM, Mieyal JJ (2012) Protein-thiol oxidation and cell death: regulatory role of glutaredoxins. *Antioxid Redox Signal* 17:1748–63. doi:[10.1089/ars.2012.4644](https://doi.org/10.1089/ars.2012.4644), PMID: 22530666

216. Franco R, Panayiotidis MI, Cidlowski JA (2007) Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation. *J Biol Chem* 282:30452–65, PMID: 17724027

217. Ji L, Shen K, Jiang P, Morahan G, Wang Z (2011) Critical roles of cellular glutathione homeostasis and jnk activation in andrographolide-mediated apoptotic cell death in human hepatoma cells. *Mol Carcinog* 50:580–91. doi:[10.1002/mc.20741](https://doi.org/10.1002/mc.20741), PMID: 21319226

218. Yue P, Zhou Z, Khuri FR, Sun SY (2006) Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). *Cancer Biol Ther* 5:492–7, PMID: 16582599

219. Haouzi D, Lekehal M, Tinel M, Vadrot N, Caussanel L, Lettéron P, Moreau A, Feldmann G, Fau D, Pessayre D (2001) Prolonged, but not acute, glutathione depletion promotes Fas-mediated mitochondrial permeability transition and apoptosis in mice. *Hepatology* 33:1181–8

220. Armstrong JS, Jones DP (2002) Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in Bcl-2 overexpressing HL60 cells. *FASEB J* 16:1263–5, PMID: 12060676

221. Chernyak BV (1997) Redox regulation of the mitochondrial permeability transition pore. *Biosci Rep* 17:293–302, PMID: 9337484

222. Sato T, Machida T, Takahashi S, Iyama S, Sato Y, Kuribayashi K, Takada K, Oku T, Kawano Y, Okamoto T, Takimoto R, Matsunaga T, Takayama T, Takahashi M, Kato J, Niitsu Y (2004) Fas-mediated apoptosome formation is dependent on reactive oxygen species derived from mitochondrial permeability transition in Jurkat cells. *J Immunol* 173:285–96, PMID: 15210786

223. D'Alessio M, De Nicola M, Coppola S, Gualandi G, Pugliese L, Cerella C, Cristofanon S, Civitareale P, Ciriolo MR, Bergamaschi A, Magrini A, Ghibelli L (2005) Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis. *FASEB J* 19:1504–6, PMID: 15972297

[PubMed](#) [Google Scholar](#)

224. Kanno T, Nishizaki T (2001) Sphingosine induces apoptosis in hippocampal neurons and astrocytes by activating caspase-3/-9 via a mitochondrial pathway linked to SDK/14-3-3 protein/Bax/cytochrome c. *J Cell Physiol* 226:2329–37.
doi:[10.1002/jcp.22571](https://doi.org/10.1002/jcp.22571), PMID: 21660956

[Google Scholar](#)

225. Guha P, Dey A, Sen R, Chatterjee M, Chattopadhyay S, Bandyopadhyay SK (2011) Intracellular GSH depletion triggered mitochondrial Bax translocation to accomplish resveratrol-induced apoptosis in the U937 cell line. *J Pharmacol Exp Ther* 336:206–14. doi:[10.1124/jpet.110.171983](https://doi.org/10.1124/jpet.110.171983), PMID: 20876229

[CAS](#) [PubMed](#) [Google Scholar](#)

226. Giorgi C, Baldassari F, Bononi A, Bonora M, De Marchi E, Marchi S, Missiroli S, Paterniani S, Rimessi A, Suski JM, Wieckowski MR, Pinton P (2012) Mitochondrial Ca(2+) and apoptosis. *Cell Calcium* 52:36–43. doi:[10.1016/j.ceca.2012.02.008](https://doi.org/10.1016/j.ceca.2012.02.008), PMID: 22480931

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

227. Jin M, Yaung J, Kannan R, He S, Ryan SJ, Hinton DR (2005) Hepatocyte growth factor protects RPE cells from apoptosis induced by glutathione depletion. *Invest Ophthalmol Vis Sci* 46:4311–19, PMID: 16249513

228. Robillard JM, Gordon GR, Choi HB, Christie BR, MacVicar BA (2011) Glutathione restores the mechanism of synaptic plasticity in aged mice to that of the adult. *PLoS One* 6:e20676. doi:[10.1371/journal.pone.0020676](https://doi.org/10.1371/journal.pone.0020676), PMID: 21655192

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

229. Steullet P, Neijt HC, Cuénod M, Do KQ (2006) Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. *Neuroscience* 137:807–19, PMID: 16330153

[CAS](#) [PubMed](#) [Google Scholar](#)

230. Abramov AY, Canevari L, Duchen MR (2003) Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. *J Neurosci* 23:5088–95, PMID: 12832532

[CAS](#) [PubMed](#) [Google Scholar](#)

231. Dallas M, Boycott HE, Atkinson L, Miller A, Boyle JP, Pearson HA, Peers C (2007) Hypoxia suppresses glutamate transport in astrocytes. *J Neurosci* 27:3946–55, PMID: 17428968

[CAS](#) [PubMed](#) [Google Scholar](#)

232. Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT (1989) Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. *Neuron* 2:1547–58, PMID: 2576375

[CAS](#) [PubMed](#) [Google Scholar](#)

- 233.** Juurlink BH (1997) Response of glial cells to ischemia: roles of reactive oxygen species and glutathione. *Neurosci Biobehav Rev* 21:151–66, PMID: 9062938

[CAS](#) [PubMed](#) [Google Scholar](#)

- 234.** Stewart VC, Stone R, Gegg ME, Sharpe MA, Hurst RD, Clark JB, Heales SJ (2002) Preservation of extracellular glutathione by an astrocyte derived factor with properties comparable to extracellular superoxide dismutase. *J Neurochem* 83:984–91, PMID: 12421371

[CAS](#) [PubMed](#) [Google Scholar](#)

- 235.** Dringen R, Pfeiffer B, Hamprecht B (1999) Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. *J Neurosci* 19:562–9, PMID: 9880576

[CAS](#) [PubMed](#) [Google Scholar](#)

- 236.** Dringen R, Gutterer JM, Gros C, Hirrlinger J (2001) Aminopeptidase N mediates the utilization of the GSH precursor CysGly by cultured neurons. *J Neurosci Res* 66:1003–8, PMID: 11746430

[CAS](#) [PubMed](#) [Google Scholar](#)

- 237.** Aoyama K, Watabe M, Nakaki T (2008) Regulation of neuronal glutathione synthesis. *J Pharmacol Sci* 108:227–38, PMID: 19008644

[CAS](#) [PubMed](#) [Google Scholar](#)

- 238.** Lertratanangkoon K, Wu CJ, Savaraj N, Thomas ML (1997) Alterations of DNA methylation by glutathione depletion. *Cancer Lett* 120:149–56, PMID: 9461031

239. Campos AC, Molognoni F, Melo FH, Galdieri LC, Carneiro CR, D'Almeida V, Correa M, Jasiulionis MG (2007) Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. *Neoplasia* 9:1111–21, PMID: 18084618

240. Hartnett L, Egan LJ (2012) Inflammation, DNA methylation and colitis-associated cancer. *Carcinogenesis* 33:723–31. doi:[10.1093/carcin/bgs006](https://doi.org/10.1093/carcin/bgs006), PMID: 22235026

241. Wachsman JT (1997) DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis. *Mutat Res* 375:1–8, PMID: 9129674

242. Weitzman SA, Turk PW, Milkowski DH, Kozlowski K (1994) Free radical adducts induce alterations in DNA cytosine methylation. *Proc Natl Acad Sci U S A* 91:1261–4, PMID: 8108398

243. Kuchino Y, Mori F, Kasai H, Inoue H, Iwai S, Miura K, Ohtsuka E, Nishimura S (1987) Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. *Nature* 327:77–9, PMID: 3574469

244. Hitchler MJ, Domann FE (2007) An epigenetic perspective on the free radical theory of development. *Free Radic Biol Med* 43:1023–36, PMID: 17761298

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

245. McCaddon A, Regland B, Hudson P, Davies G (2002) Functional vitamin B(12) deficiency and Alzheimer disease. *Neurology* 58:1395–9, PMID: 12011287

[CAS](#) [PubMed](#) [Google Scholar](#)

246. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M (2008)) How environmenta and genetic factors combine to cause autism: a redox/methylation hypothesis. *Neurotoxicol* 29:190–201, PMID: 1803-1821

[CAS](#) [Google Scholar](#)

247. Looney JM, Childs HM (1934) The lactic acid and glutathione content of the blood of schizophrenic patients. *J Clin Invest* 13:963–8, PMID: 16694262

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

248. Rybka J, Kędziora-Kornatowska K, Banaś-Leżańska P, Majsterek I, Carvalho LA, Cattaneo A, Anacker C, Kędziora J (2013) Interplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression. *Free Radic Biol Med* 63:187–194.
doi:[10.1016/j.freeradbiomed.2013.05.019](https://doi.org/10.1016/j.freeradbiomed.2013.05.019), PMID: 23707456

[CAS](#) [PubMed](#) [Google Scholar](#)

249. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2011) Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis/chronic fatigue syndrome: another pathway that may be

associated with coronary artery disease and neuroprogression in depression. Neuro Endocrinol Lett 32:133–40, PMID: 21552194

[PubMed](#) [Google Scholar](#)

250. Kaddurah-Daouk R, Yuan P, Boyle SH, Matson W, Wang Z, Zeng ZB, Zhu H, Dougherty GG, Yao JK, Chen G, Guitart X, Carlson PJ, Neumeister A, Zarate C, Krishnan RR, Manji HK, Drevets W (2012) Cerebrospinal fluid metabolome in mood disorders—remission state has a unique metabolic profile. Sci Rep 2:667, PMID: 22993692

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

251. Stefanescu C, Ciobica A (2012) The relevance of oxidative stress status in first episode and recurrent depression. J Affect Disorder 20;143(1-3):34–8.
doi:[10.1016/j.jad.2012.05.022](https://doi.org/10.1016/j.jad.2012.05.022)

[Google Scholar](#)

252. Gibson SA, Korade Ž, Shelton RC (2012) Oxidative stress and glutathione response in tissue cultures from persons with major depression. J Psychiatr Res 46:1326–32.
doi:[10.1016/j.jpsychires.2012.06.008](https://doi.org/10.1016/j.jpsychires.2012.06.008), PMID: 22841833

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

253. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Yatham LN, Young LT (2011) Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Int J Neuropsychopharmacol 14:1069–74.
doi:[10.1017/S1461145711000617](https://doi.org/10.1017/S1461145711000617), PMID: 21733244

[CAS](#) [PubMed](#) [Google Scholar](#)

254. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT (2011) Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. *Int J Neuropsychopharmacol* 14:123–30.
doi:[10.1017/S1461145710000805](https://doi.org/10.1017/S1461145710000805), PMID: 20633320

[CAS](#) [PubMed](#) [Google Scholar](#)

255. Rose S, Melnyk S, Pavliv O, Bai S, Nick TG, Frye RE, James SJ (2012) Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. *Transl Psychiatry* 2:e134. doi:[10.1038/tp.2012.61](https://doi.org/10.1038/tp.2012.61), PMID: 22781167

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

256. Mathew SJ, Murrough JW, Mao X, Pillemeyer S, Shungu DC (2010) Proton magnetic resonance spectroscopy measurement of brain glutathione supports increased oxidative stress in major depressive disorder. 49th American College of Neuropsychopharmacology Annual Meeting, Miami, Fl., December 5. Poster Session 1: 153

257. Do KQ, Trabesinger AH, Kirsten-Krüger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuénod M (2000) Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. *Eur J Neurosci* 12:3721–8, PMID: 11029642

[CAS](#) [PubMed](#) [Google Scholar](#)

258. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, Takanashi J, Matsuda T, Shimizu E, Ikehira H, Iyo M, Hashimoto K (2008) Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a ³T ¹H-MRS study. *PLoS One* 3:e1944, PMID: 18398470

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

259. Berk M, Johansson S, Wray NR, Williams L, Olsson C, Haavik J, Bjerkeset O (2011) Glutamate cysteine ligase (GCL) and self reported depression: an association study from the HUNT. *J Affect Disord* 131:207–13. doi:[10.1016/j.jad.2010.12.019](https://doi.org/10.1016/j.jad.2010.12.019), PMID: 21277635

[CAS](#) [PubMed](#) [Google Scholar](#)

260. Maes M, Van de Vyvere J, Vandoolaeghe E, Bril T, Demedts P, Wauters A, Neels H (1996) Alterations in iron metabolism and the erythron in major depression: further evidence for a chronic inflammatory process. *J Affect Disord* 40:23–33. doi:[10.1016/0165-0327\(96\)00038-9](https://doi.org/10.1016/0165-0327(96)00038-9). PMID: 8882911

[CAS](#) [PubMed](#) [Google Scholar](#)

261. Edwards R, Peet M, Shay J, Horrobin D (1998) Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. *J Affect Disord* 48:149–55. doi:[10.1016/S0165-0327\(97\)00166-3](https://doi.org/10.1016/S0165-0327(97)00166-3). PMID: 9543204

[CAS](#) [PubMed](#) [Google Scholar](#)

262. Peet M, Murphy B, Shay J, Horrobin D (1998) Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. *Biol Psychiatry* 43:315–9, PMID: 9513745

[CAS](#) [PubMed](#) [Google Scholar](#)

263. Richards RS, Wang L, Jelinek H (2007) Erythrocyte oxidative damage in chronic fatigue syndrome. *Arch Med Res* 38:94–8

[CAS](#) [PubMed](#) [Google Scholar](#)

264. Raftos JE, Whillier S, Kuchel PW (2010) Glutathione synthesis and turnover in the human erythrocyte: alignment of a model based on detailed enzyme kinetics with experimental data. *J Biol Chem* 285:23557–67. doi:[10.1074/jbc.M109.067017](https://doi.org/10.1074/jbc.M109.067017), PMID: 20498365

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

265. Tavazzi B, Amorini AM, Fazzina G, Di Pierro D, Tuttobene M, Giardina B, Lazzarino G (2001) Oxidative stress induces impairment of human erythrocyte energy metabolism through the oxygen radical-mediated direct activation of AMP-deaminase. *J Biol Chem* 276:48083–92, PMID: 11675377

[CAS](#) [PubMed](#) [Google Scholar](#)

266. Pandey KB, Rizvi SI (2010) Markers of oxidative stress in erythrocytes and plasma during aging in humans. *Oxid Med Cell Longev* 3:2–12. doi:[10.4161/oxim.3.1.10476](https://doi.org/10.4161/oxim.3.1.10476), PMID: 20716923

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

267. Morris G, Maes M (2013) Case definitions and diagnostic criteria for myalgic encephalomyelitis and chronic fatigue syndrome: from clinical-consensus to evidence-based case definitions. *Neuro-Endocrinol Lett* 34:185–99, PMID: 23685416

[PubMed](#) [Google Scholar](#)

268. Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S, Dyke JP, Medow MS, Natelson BH, Stewart JM, Mathew SJ (2012) Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. *NMR Biomed* 25:1073–87. doi:[10.1002/nbm.2772](https://doi.org/10.1002/nbm.2772), PMID: 22281935

269. Puri BK, Agour M, Gunatilake KD, Fernando KA, Gurusinghe AI, Treasaden IH (2009) An in vivo proton neurospectroscopy study of cerebral oxidative stress in myalgic encephalomyelitis (chronic fatigue syndrome). *Prostaglandins Leukot Essent Fatty Acids* 81:303–5. doi:[10.1016/j.plefa.2009.10.002](https://doi.org/10.1016/j.plefa.2009.10.002), PMID: 19906518

270. Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJ (2005) Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. *Free Radic Biol Med* 39:584–9, PMID: 16085177

271. Richards RS, Roberts TK, Dunstan RH, McGregor NR, Butt HL (2000) Free radicals in chronic fatigue syndrome: cause or effect? *Redox Rep* 5:146–7

272. Fulle S, Mecocci P, Fanó G, Vecchiet I, Vecchini A, Raciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF (2000) Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. *Free Radic Biol Med* 29:1252–9, PMID: 11118815

273. Logan AC, Wong C (2001) Chronic fatigue syndrome: oxidative stress and dietary modifications. *Altern Med Rev* 6:450–9, PMID: 11703165

- 274.** Jammes Y, Steinberg JG, Mambrini O, Brégeon F, Delliaux S (2005) Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. *J Intern Med* 257:299–310, PMID: 15715687

[CAS](#) [PubMed](#) [Google Scholar](#)

- 275.** Bested AC, Saunders PR, Logan AC (2001) Chronic fatigue syndrome: neurological findings may be related to blood–brain barrier permeability. *Med Hypotheses* 57:231–7, PMID: 11461179

[CAS](#) [PubMed](#) [Google Scholar](#)

- 276.** Kim HG, Cho JH, Yoo SR, Lee JS, Han JM, Lee NH, Ahn YC, Son CG (2013) Antifatigue effects of *Panax ginseng* C.A. Meyer: a randomised, double-blind, placebo-controlled trial. *PLoS One* 8:e61271

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

- 277.** Kim HG, Yoo SR, Park HJ, Son CG (2013) Indirect moxibustion (CV4 and CV8) ameliorates chronic fatigue: a randomized, double-blind, controlled study. *J Altern Complement Med* 19:134–40. doi:[10.1089/acm.2011.0503](https://doi.org/10.1089/acm.2011.0503), PMID: 22757691

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

- 278.** Ding W, Liu Y (2011) Genistein attenuates genioglossus muscle fatigue under chronic intermittent hypoxia by down-regulation of oxidative stress level and up-regulation of antioxidant enzyme activity through ERK1/2 signaling pathway. *Oral Dis* 17:677–84. doi:[10.1111/j.1601-0825.2011.01822.x](https://doi.org/10.1111/j.1601-0825.2011.01822.x), PMID: 21729219

[PubMed](#) [Google Scholar](#)

279. Liu CZ, Lei B (2012) Effect of acupuncture on serum malonaldehyde content, superoxide dismutase and glutathione peroxidase activity in chronic fatigue syndrome rats. *Zhen Ci Yan Jiu* 37:38–40, PMID: 22574567

[PubMed](#) [Google Scholar](#)

280. Sachdeva AK, Kuhad A, Tiwari V, Chopra K (2009) Epigallocatechin gallate ameliorates chronic fatigue syndrome in mice: behavioral and biochemical evidence. *Behav Brain Res* 205:414–20. doi:[10.1016/j.bbr.2009.07.020](https://doi.org/10.1016/j.bbr.2009.07.020), PMID: 19643148

[CAS](#) [PubMed](#) [Google Scholar](#)

281. Kumar A, Garg R (2009) Protective effects of antidepressants against chronic fatigue syndrome-induced behavioral changes and biochemical alterations. *Fundam Clin Pharmacol* 23:89–95. doi:[10.1111/j.1472-8206.2008.00638.x](https://doi.org/10.1111/j.1472-8206.2008.00638.x), PMID: 19207541

[CAS](#) [PubMed](#) [Google Scholar](#)

282. Kumar A, Garg R (2008) Kumar P (2008) Nitric oxide modulation mediates the protective effect of trazodone in a mouse model of chronic fatigue syndrome. *Pharmacol Rep* 60(5):664–72, PubMed PMID: 19066412

[CAS](#) [PubMed](#) [Google Scholar](#)

283. Dhir A, Kulkarni SK (2008) Venlafaxine reverses chronic fatigue-induced behavioral, biochemical and neurochemical alterations in mice. *Pharmacol, Biochem Behav* 89:563–71. doi:[10.1016/j.pbb.2008.02.011](https://doi.org/10.1016/j.pbb.2008.02.011), PMID: 18336891

[CAS](#) [Google Scholar](#)

284. Singal A, Kaur S, Tirkey N, Chopra K (2005) Green tea extract and catechin ameliorate chronic fatigue-induced oxidative stress in mice. *J Med Food* 8:47–52,

285. Singh A, Garg V, Gupta S, Kulkarni SK (2002) Role of antioxidants in chronic fatigue syndrome in mice. Indian J Exp Biol 40:1240–4, PMID:13677625

286. Morris G, Maes M (2013) Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med 11:205. doi:[10.1186/1741-7015-11-205](https://doi.org/10.1186/1741-7015-11-205), PMID: 24229326

287. Morris G, Maes M (2014) Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis 29(1):19–36

288. Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M (2011) In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35(3):744–59. doi:[10.1016/j.pnpbp.2010.08.026](https://doi.org/10.1016/j.pnpbp.2010.08.026), PubMed PMID: 20828592

289. Vialou V, Feng J, Robison AJ, Nestler EJ (2013) Epigenetic mechanisms of depression and antidepressant action. *Annu Rev Pharmacol Toxicol* 53:59–87.
doi:[10.1146/annurev-pharmtox-010611-134540](https://doi.org/10.1146/annurev-pharmtox-010611-134540), PMID: 23020296

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

290. Menzies V, Lyon DE, Archer KJ, Zhou Q, Brumelle J, Jones KH, Gao G, York TP, Jackson-Cook C (2013) Epigenetic alterations and an increased frequency of micronuclei in women with fibromyalgia. *Nurs Res Pract* 2013:795784.
doi:[10.1155/2013/795784](https://doi.org/10.1155/2013/795784), PMID: 24058735

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

291. Rönnbäck L, Hansson E (2004) On the potential role of glutamate transport in mental fatigue. *J Neuroinflammation* 1:22, PMID: 15527505

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

292. Moylan S, Maes M, Wray NR, Berk M (2013) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. *Mol Psychiatry* 18:595–606. doi:[10.1038/mp.2012.33](https://doi.org/10.1038/mp.2012.33), PMID: 22525486

[CAS](#) [PubMed](#) [Google Scholar](#)

293. Anderson G, Maes M (2013) Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. *Curr Pharm Des* [Epub ahead of print] PubMed PMID: 24180395.

294. Keane PC, Kurzawa M, Blain PG, Morris CM (2011) Mitochondrial dysfunction in Parkinson's disease. *Parkinsons Dis* 2011:716871. doi:[10.4061/2011/716871](https://doi.org/10.4061/2011/716871), PMID: 21461368

295. Hsu M, Srinivas B, Kumar J, Subramanian R, Andersen J (2005) Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. *J Neurochem* 92:1091–103, PMID: 15715660

296. Auchère F, Santos R, Planamente S, Lesuisse E, Camadro JM (2008) Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich's ataxia. *Hum Mol Genet* 17:2790–802. doi:[10.1093/hmg/ddn178](https://doi.org/10.1093/hmg/ddn178), PMID: 18562474

297. Friedlich AL, Smith MA, Zhu X, Takeda A, Nunomura A, Moreira PI, Perry G (2009) Oxidative stress in Parkinson's disease. *Open Pathology J* 3:38–42

298. Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and human disease. *Toxicology* 283:65–87. doi:[10.1016/j.tox.2011.03.001](https://doi.org/10.1016/j.tox.2011.03.001), PMID: 21414382

299. Valko M, Morris H, Cronin MT (2005) Metals, toxicity and oxidative stress. *Curr Med Chem* 12:1161–208, PMID: 15892631

300. Morris G, Maes M (2014) Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-

inflammatory, oxidative and nitrosative stress pathways. *Metab Brain Dis* 29:19–36.
doi:[10.1007/s11011-013-9435-x](https://doi.org/10.1007/s11011-013-9435-x), PMID: 24557875

[CAS](#) [PubMed](#) [Google Scholar](#)

301. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA (2007) Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. *Pulm Pharmacol Ther* 20:9–22, PMID: 16458553

[CAS](#) [PubMed](#) [Google Scholar](#)

302. Cotgreave IA (1997) *N*-acetylcysteine: pharmacological considerations and experimental and clinical applications. *Adv Pharmacol* 38:205–27, PMID: 8895810

[CAS](#) [PubMed](#) [Google Scholar](#)

303. Jain A, Mårtensson J, Stole E, Auld PA, Meister A (1991) Glutathione deficiency leads to mitochondrial damage in brain. *Proc Natl Acad Sci U S A* 88:1913–7, PMID: 2000395

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

304. Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson's disease: is this the elephant in the room? *Biomed Pharmacother* 62:236–49

[CAS](#) [PubMed](#) [Google Scholar](#)

305. De Flora S, Bennicelli C, Camoirano A, Serra D, Romano M, Rossi GA, Morelli A, De Flora A (1985) In vivo effects of *N*-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compounds. *Carcinogenesis* 6:1735–45

306. Hoffer E, Baum Y, Tabak A, Taitelman U (1996) *N*-acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity. *Toxicol Lett* 84:7–12

[CAS](#) [PubMed](#) [Google Scholar](#)

307. Corcoran GB, Wong BK (1986) Role of glutathionein prevention of acetaminophen-induced hepatotoxicity by *N*-acetyl-L-cysteine in vivo: studies with *N*-acetyl-D-cysteine in mice. *J Pharmacol Exp Ther* 238:54–61

[CAS](#) [PubMed](#) [Google Scholar](#)

308. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA (2007) *N*-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency. *Curr Opin Pharmacol* 7:355–9

[CAS](#) [PubMed](#) [Google Scholar](#)

309. Samuni Y, Goldstein S, Dean OM, Berk M (2013) The chemistry and biological activities of *N*-acetylcysteine. *Biochim Biophys Acta* 1830:4117–29.
doi:[10.1016/j.bbagen.2013.04.016](https://doi.org/10.1016/j.bbagen.2013.04.016)

[CAS](#) [PubMed](#) [Google Scholar](#)

310. Arranz L, Fernández C, Rodríguez A, Ribera JM, De la Fuente M (2008) The glutathione precursor *N*-acetylcysteine improves immune function in postmenopausal women. *Free Radic Biol Med* 45:1252–62.
doi:[10.1016/j.freeradbiomed.2008.07.014](https://doi.org/10.1016/j.freeradbiomed.2008.07.014)

[CAS](#) [PubMed](#) [Google Scholar](#)

311. Banner W Jr, Koch M, Capin DM, Hopf SB, Chang S, Tong TG (1986) Experimental chelation therapy in chromium, lead, and boron intoxication with *N*-acetylcysteine and other compounds. *Toxicol Appl Pharmacol* 83:142–7

[CAS](#) [PubMed](#) [Google Scholar](#)

312. de Quay B, Malinverni R, Lauterburg BH (1992) Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral *N*-acetylcysteine. *AIDS* 6:815–9

[PubMed](#) [Google Scholar](#)

313. Akerlund B, Jarstrand C, Lindeke B, Sonnerborg A, Akerblad AC, Rasool O (1996) Effect of *n*-acetylcysteine (NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. *Eur J Clin Pharmacol* 50:457–61

[CAS](#) [PubMed](#) [Google Scholar](#)

314. Herzenberg LA, De Rosa SC, Dubs JG, Roederer M, Anderson MT, Ela SW, Deresinski SC, Herzenberg LA (1997) Glutathione deficiency is associated with impaired survival in HIV disease. *Proc Natl Acad Sci U S A* 94:1967–72

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

315. Chen F, Lewis W, Hollander JM, Baseler W, Finkel MS (1985) *N*-acetylcysteine reverses cardiac myocyte dysfunction in HIV-Tat proteinopathy. *J Appl Physiol* 113:105–13. doi:[10.1152/japplphysiol.00068.2012](https://doi.org/10.1152/japplphysiol.00068.2012)

[Google Scholar](#)

316. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI (2008) *N*-acetyl cysteine for depressive symptoms in bipolar disorder—a double-

blind randomized placebo-controlled trial. *Biol Psychiatry* 64:468–75.

doi:[10.1016/j.biopsych.2008.04.022](https://doi.org/10.1016/j.biopsych.2008.04.022), PMID: 18534556

[CAS](#) [PubMed](#) [Google Scholar](#)

317. Magalhães PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M (2011) *N*-acetylcysteine for major depressive episodes in bipolar disorder. *Rev Bras Psiquiatr* 33:374–8, PMID: 22189927

[PubMed](#) [Google Scholar](#)

318. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS (2011) The efficacy of *N*-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. *J Affect Disord* 135:389–94.
doi:[10.1016/j.jad.2011.06.005](https://doi.org/10.1016/j.jad.2011.06.005)

[CAS](#) [PubMed](#) [Google Scholar](#)

319. Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S (2013) *N*-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. *Clin Neuropharmacol* 36:185–92

[CAS](#) [PubMed](#) [Google Scholar](#)

320. Ghanizadeh A, Moghimi-Sarani E (2013) A randomized double blind placebo controlled clinical trial of *N*-acetylcysteine added to risperidone for treating autistic disorders. *BMC Psychiatry* 13:196. doi:[10.1186/1471-244X-13-196](https://doi.org/10.1186/1471-244X-13-196)

321. Child DF, Hudson PR, Jones H, Davies GK, De P, Mukherjee S, Brain AM, Williams CP, Harvey JN (2004) The effect of oral folic acid on glutathione, glycaemia and lipids in type 2 diabetes. *Diabetes Nutr Metab* 17:95–102

[CAS](#) [PubMed](#) [Google Scholar](#)

322. Chanson A, Rock E, Martin JF, Liotard A, Brachet P (2007) Preferential response of glutathione-related enzymes to folate-dependent changes in the redox state of rat liver. *Eur J Nutr* 46:204–12

[CAS](#) [PubMed](#) [Google Scholar](#)

323. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M (2012) L-Methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. *Am J Psychiatry* 169:1267–74

[PubMed](#) [Google Scholar](#)

324. Reynolds EH (2002) Folic acid, ageing, depression, and dementia. *BMJ* 324:1512–5, PMID: 12077044

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

325. Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba BM, Diana R, La Greca P, Le Grazie C (1993) Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. *Aging* 5:63–71

326. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T (1997) Folate, vitamin B12, and homocysteine in major depressive disorder. *Am J Psychiatry* 154:426–8

327. Guaraldi GP, Fava M, Mazzi F, la Greca P (1993) An open trial of methyltetrahydrofolate in elderly depressed patients. *Ann Clin Psychiatry* 5:101–5

328. Stahl SM (2007) Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. *CNS Spectr* 12:739–44, PMID: 17934378

329. Liu J (2008) The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. *Neurochem Res* 33:194–203

330. Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA (2012) Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of sirtuin 1 and sirtuin 3. *Obesity (Silver Spring)* 20:1974–83

331. Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F (2008) Functions of coenzyme Q10 in inflammation and gene expression. *Biofactors* 32:179–83

[CAS](#) [PubMed](#) [Google Scholar](#)

332. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydaghs N, Bosmans E (2009) Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. *Neuro-Endocrinol Lett* 30:462–9

[CAS](#) [PubMed](#) [Google Scholar](#)

333. Aboul-Fotouh S (2013) Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats. *Pharmacol, Biochem Behav* 104:105–12

[CAS](#) [Google Scholar](#)

334. Forester BP, Zuo CS, Ravichandran C, Harper DG, Du F, Kim S, Cohen BM, Renshaw PF (2012) Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. *J Geriatr Psychiatry Neurol* 25:43–50.
doi:[10.1177/0891988712436688](https://doi.org/10.1177/0891988712436688), PMID: 22467846

[PubMed](#) [Google Scholar](#)

335. Jeong YY, Park HJ, Cho YW, Kim EJ, Kim GT, Mun YJ, Lee JD, Shin JH, Sung NJ, Kang D, Han J (2012) Aged red garlic extract reduces cigarette smoke extract-induced cell death in human bronchial smooth muscle cells by increasing intracellular glutathione levels. *Phytother Res* 26:18–25. doi:[10.1002/ptr.3502](https://doi.org/10.1002/ptr.3502)

[CAS](#) [PubMed](#) [Google Scholar](#)

336. Rodríguez-Ramiro I, Ramos S, Bravo L, Goya L, Martín MÁ (2011) Procyanidin B2 and a cocoa polyphenolic extract inhibit acrylamide-induced apoptosis in human Caco-2 cells by preventing oxidative stress and activation of JNK pathway. *J Nutr Biochem* 22:1186–94. doi:[10.1016/j.jnutbio.2010.10.005](https://doi.org/10.1016/j.jnutbio.2010.10.005)

[PubMed](#) [Google Scholar](#)

337. Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL (2013) The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. *Redox Biol* 1:45–9, PMID: 24024136

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

338. Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M (2012) New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. *Inflammopharmacol* 20:127–50

[CAS](#) [Google Scholar](#)

339. Nguyen T, Sherratt PJ, Pickett CB (2003) Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. *Annu Rev Pharmacol Toxicol* 43:233–60

[CAS](#) [PubMed](#) [Google Scholar](#)

340. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, Talalay P (2002) Direct evidence that sulphhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. *Proc Natl Acad Sci U S A* 99:11908–13

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

- 341.** Harvey CJ, Thimmulappa RK, Singh A, Blake DJ, Ling G, Wakabayashi N, Fujii J, Myers A, Biswal S (2009) Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. *Free Radic Biol Med* 46:443–53. doi:[10.1016/j.freeradbiomed.2008.10.040](https://doi.org/10.1016/j.freeradbiomed.2008.10.040)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

- 342.** Tsai CC, Chen HS, Chen SL, Ho YP, Ho KY, Wu YM, Hung CC (2005) Lipid peroxidation: a possible role in the induction and progression of chronic periodontitis. *J Periodontal Res* 40:378–84

[CAS](#) [PubMed](#) [Google Scholar](#)

- 343.** Dias VV, Brissos S, Cardoso C, Andreazza AC, Kapczinski F (2009) Serum homocysteine levels and cognitive functioning in euthymic bipolar patients. *J Affect Disord* 113:285–90

[CAS](#) [PubMed](#) [Google Scholar](#)

- 344.** Godman CA, Chheda KP, Hightower LE, Perdrizet G, Shin DG, Giardina C (2010) Hyperbaric oxygen induces a cytoprotective and angiogenic response in human microvascular endothelial cells. *Cell Stress Chaperones* 15:431–42

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

- 345.** Thom SR (1985) Oxidative stress is fundamental to hyperbaric oxygen therapy. *J Appl Physiol* 106:988–95. doi:[10.1152/japplphysiol.91004.2008](https://doi.org/10.1152/japplphysiol.91004.2008), PMID: 18845776

[Google Scholar](#)

- 346.** Soejima Y, Ostrowski RP, Manaenko A, Fujii M, Tang J, Zhang JH (2012) Hyperbaric oxygen preconditioning attenuates hyperglycemia enhanced hemorrhagic

347. Avtan SM, Kaya M, Orhan N, Arslan A, Arican N, Toklu AS, Gürses C, Elmas I, Kucuk M, Ahishali B (2011) The effects of hyperbaric oxygen therapy on blood-brain barrier permeability in septic rats. *Brain Res* 1412:63–72. doi:[10.1016/j.brainres.2011.07.020](https://doi.org/10.1016/j.brainres.2011.07.020)

348. Haapaniemi T, Sirsjö A, Nylander G, Larsson J (1995) Hyperbaric oxygen treatment attenuates glutathione depletion and improves metabolic restitution in postischemic skeletal muscle. *Free Radic Res* 23:91–101

349. Purucker E, Lutz J (1992) Effect of hyperbaric oxygen treatment and perfluorochemical administration on glutathione status of the lung. *Adv Exp Med Biol* 317:131–6

350. Li Q, Li J, Zhang L, Wang B, Xiong L (2007) Preconditioning with hyperbaric oxygen induces tolerance against oxidative injury via increased expression of heme oxygenase-1 in primary cultured spinal cord neurons. *Life Sci* 80:1087–93. doi:[10.1016/j.lfs.2006.11.043](https://doi.org/10.1016/j.lfs.2006.11.043)

351. Rothfuss A, Speit G (2002) Investigations on the mechanism of hyperbaric oxygen (HBO)-induced adaptive protection against oxidative stress. *Mutat Res* 508:157–65

352. Speit G, Dennog C, Eichhorn U, Rothfuss A, Kaina B (2000) Induction of heme oxygenase-1 and adaptive protection against the induction of DNA damage after hyperbaric oxygen treatment. *Carcinogenesis* 21:1795–9

353. Surh YJ, Kundu JK, Na HK (2008) Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. *Planta Med* 74:1526–39

354. Biswas SK, McClure D, Jimenez LA, Megson IL, Rahman I (2005) Curcumin induces glutathione biosynthesis and inhibits NF- κ B activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. *Antioxid Redox Signal* 7:32–41

355. Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I (2008) Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 294:L478–488

356. Garg R, Gupta S, Maru GB (2008) Dietary curcumin modulates transcriptional regulators of phase I and phase II enzymes in benzo[a]pyrene-treated mice: mechanism of its anti-initiating action. *Carcinogenesis* 29:1022–32

357. Natarajan VT, Singh A, Kumar AA (2010) Transcriptional upregulation of Nrf2-dependent phase II detoxification genes in the involved epidermis of vitiligo vulgaris. *J Invest Dermatol* 130:2781–9

358. Shen G, Xu C, Hu R (2006) Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. *Mol Cancer Ther* 5:39–51

359. McNally SJ, Harrison EM, Ross JA, Garden OJ, Wigmore SJ (2007) Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. *Int J Mol Med* 19:165–72

360. Rushworth SA, Ogborne RM, Charalambos CA, O'Connell MA (2006) Role of protein kinase C δ in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. *Biochem Biophys Res Commun* 341:1007–16

361. Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, Goel A, Tripathi CB (2013) Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. *Phytother Res* doi: doi:[10.1002/ptr.5025](https://doi.org/10.1002/ptr.5025)

362. Kulkarni S, Dhir A, Akula KK (2009) Potentials of curcumin as an antidepressant. *Sci World J* 9:1233–41. doi:[10.1100/tsw.2009.137](https://doi.org/10.1100/tsw.2009.137)

[CAS](#) [Google Scholar](#)

363. Gupta A, Vij G, Sharma S, Tirkey N, Rishi P, Chopra K (2009) Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model. *Immunobiol* 214:33–9

[CAS](#) [Google Scholar](#)

364. Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, Cuadrado A (2004) Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. *J Biol Chem* 279:8919–29

[CAS](#) [PubMed](#) [Google Scholar](#)

365. Kong AN, Yu R, Hebbar V, Chen C, Owuor E, Hu R, Ee R, Mandlekar S (2001) Signal transduction events elicited by cancer prevention compounds. *Mutat Res* 480–481:231–41

[PubMed](#) [Google Scholar](#)

366. Wondrak GT, Cabello CM, Villeneuve NF, Zhang S, Ley S, Li Y, Sun Z, Zhang DD (2008) Cinnamoyl-based Nrf2-activators targeting human skin cell photo-oxidative stress. *Free Radic Biol Med* 45:385–95

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

367. Moriya J, Chen R, Yamakawa J, Sasaki K, Ishigaki Y, Takahshi T (2011) Resveratrol improves hippocampal atrophy in chronic fatigue mice by enhancing neurogenesis

and inhibiting apoptosis of granular cells. *Biol Pharm Bull* 34:354–9

[CAS](#) [PubMed](#) [Google Scholar](#)

368. Niu K, Hozawa A, Kuriyama S, Ebihara S, Guo HM, Nakaya N, Ohmori-Matsuda K, Takahashi H, Masamune Y, Asada M, Sasaki S, Arai H, Awata S, Nagatomi R, Tsuji I (2009) Green tea consumption is associated with depressive symptoms in the elderly. *Am J Clin Nutr* 90:1615–22

[CAS](#) [PubMed](#) [Google Scholar](#)

369. Han SG, Han SS, Toborek M, Hennig B (2012) EGCG protects endothelial cells against PCB 126-induced inflammation through inhibition of AhR and induction of Nrf2-regulated genes. *Toxicol Appl Pharmacol* 261:181–8

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

370. Steele ML, Fuller S, Patel M, Kersaitis C, Ooi L, Münch G (2013) Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells. *Redox Biol* 1:441–5. doi:[10.1016/j.redox.2013.08.006](https://doi.org/10.1016/j.redox.2013.08.006)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

371. Lin SX, Lisi L, Russo CD, Polak PE, Sharp A, Weinberg G, Kalinin S, Feinstein DL (2011) The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. *ASN Neuro* 3:e00055. doi:[10.1042/AN20100033](https://doi.org/10.1042/AN20100033)

[PubMed Central](#) [PubMed](#) [Google Scholar](#)

372. Lukashev M, Zeng M, Goelz S, Lee D, Linker R, Drukach B, VanDam A (2007) Activation of Nrf2 and modulation of disease progression in EAE models by BG-12

(dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities. *Mult Scler* 13:149

[Google Scholar](#)

- 373.** Linker RA, Gold R (2013) Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. *Curr Neurol Neurosci Rep* 13:394. doi:[10.1007/s11910-013-0394-8](https://doi.org/10.1007/s11910-013-0394-8)

[PubMed](#) [Google Scholar](#)

- 374.** Moharregh-Khiabani D, Linker RA, Gold R, Stangel M (2009) Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. *Curr Neuropharmacol* 7:60–64. doi:[10.2174/157015909787602788](https://doi.org/10.2174/157015909787602788)

[CAS](#) [PubMed Central](#) [PubMed](#) [Google Scholar](#)

- 375.** Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O’Neil GN, BG-12 Phase IIb Study Investigators (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. *Lancet* 372:1463–72

[Google Scholar](#)

- 376.** Dodd S, Maes M, Anderson G, Dean O, Moylan S, Berk M (2013) Putative neuroprotective agents in major psychoses. *Prog Neuropsychopharmacol Biol Psychiatry* 42:135–145

[CAS](#) [PubMed](#) [Google Scholar](#)

Funding

No specific funding was obtained for this specific review.

Conflict of Interests

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

Tir Na Nog, Bryn Road Seaside 87, Llanelli, SA152LW, Wales, UK

Gerwyn Morris

CRC Clinical Research Centre/Communications, Laurel Street 57, Glasgow, G11 7QT, Scotland, UK

George Anderson

Barwon Health, School of Medicine, Deakin University, P.O. Box 291, Geelong, 3220, Australia

Olivia Dean, Michael Berk & Michael Maes

Orygen Youth Health Research Centre, Poplar Road 35, Parkville, 3052, Australia

Michael Berk

Centre of Youth Mental Health, University of Melbourne, Poplar Road 35, Parkville, 3052, Australia

Michael Berk

The Florey Institute for Neuroscience and Mental Health, University of Melbourne, Kenneth Myer Building, Royal Parade 30, Parkville, 3052, Australia

Michael Berk

Department of Psychiatry, University of Melbourne, Level 1 North, Main Block, Royal Melbourne Hospital, Parkville, 3052, Australia

Michael Berk

Department of Adult Psychiatry, Medical University of Lodz, Aleksandrowska 159, Lodz, 91229, Poland

Piotr Galecki

Department of Psychiatry, Hospital Germans Trias i Pujol, Carretera de Canyet s/n. 08916,
Badalona, Spain
Marta Martin-Subero

Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Rama 4 Road
1873, Pathumwan, Bangkok, 10330, Thailand
Michael Maes

Corresponding author

Correspondence to [Michael Maes](#).

Rights and permissions

[Reprints and permissions](#)

About this article

Cite this article

Morris, G., Anderson, G., Dean, O. *et al.* The Glutathione System: A New Drug Target in Neuroimmune Disorders. *Mol Neurobiol* **50**, 1059–1084 (2014).
<https://doi.org/10.1007/s12035-014-8705-x>

Received	Accepted	Published
04 January 2014	31 March 2014	22 April 2014

Issue Date

December 2014

DOI

<https://doi.org/10.1007/s12035-014-8705-x>

Keywords

Glutathione

Oxidative and nitrosative stress

Inflammation

Cytokines

Depression

Myalgic encephalomyelitis

Chronic fatigue

Immune